This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Elanco to sell dog treatment to Dechra Pharmaceuticals for $135 million to push forward acquisition of Bayer's animal health business

( January 6, 2020, 17:14 GMT | Official Statement) -- MLex Summary: Elanco will sell to Dechra Pharmaceuticals a dog treatment named Osurnia for $135 million, the company announced in a release. Elanco said it made the sale in order to push forward its acquisition of Bayer's animal health business, which is under review in the US. The Osurnia sale is contingent upon Elanco entering into settlements with the US Federal Trade Commission and European Commission, the release said. Statement follows below: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login